| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $12,983,320 | 1 | 100 |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 0 | $0 | 1 | $12.98M | $-12.98M |
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC …
Over the last 12 months, insiders at ArriVent BioPharma, Inc. have bought $0 and sold $12.98M worth of ArriVent BioPharma, Inc. stock.
On average, over the past 5 years, insiders at ArriVent BioPharma, Inc. have bought $26M and sold $12.98M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 555,555 shares for transaction amount of $10M was made by HILLHOUSE INVESTMENT MANAGEMENT, LTD. (10 percent owner) on 2024‑01‑30.
| 2025-12-10 | Sale | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 555,555 1.6309% | $23.37 | $12.98M | +13.55% | |
| 2024-01-30 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 555,555 1.2562% | $18.00 | $10M | 0.00% | ||
| 2024-01-30 | HEALY JAMES | director | 444,444 1.0049% | $18.00 | $8M | 0.00% | ||
| 2024-01-30 | ORBIMED ADVISORS LLC | 222,222 0.5025% | $18.00 | $4M | 0.00% | |||
| 2024-01-30 | GORDON CARL L | 222,222 0.5025% | $18.00 | $4M | 0.00% |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 3929117 7.9686% | $51.16M | 1 | 1 | 0% |
| HEALY JAMES | director | 1696752 3.4411% | $22.09M | 1 | 0 | 0% |
| ORBIMED ADVISORS LLC | 1513664 3.0698% | $19.71M | 1 | 0 | 0% | |
| GORDON CARL L | 1513664 3.0698% | $19.71M | 1 | 0 | 0% |
$10,154,205 | 103 | -4.60% | $631.34M | |
$860,541,348 | 82 | -5.10% | $649.64M | |
$40,226,318 | 58 | 18.89% | $539.26M | |
$1,344,238 | 38 | 23.07% | $639.18M | |
$59,156,363 | 22 | 29.25% | $686.5M |
| Increased Positions | 71 | +62.83% | 5M | +12.23% |
| Decreased Positions | 49 | -43.36% | 3M | -8.25% |
| New Positions | 31 | New | 3M | New |
| Sold Out Positions | 15 | Sold Out | 1M | Sold Out |
| Total Postitions | 135 | +19.47% | 40M | +3.98% |